The eNose Company

What The eNose Company does

The eNose Company is a Dutch medical technology company headquartered in Zutphen, Netherlands, founded in 2013. It developed the aeoNose, a portable breath analysis device that detects volatile organic compound (VOC) patterns in exhaled breath to identify signatures associated with lung cancer, colorectal cancer, and COVID-19. The core methodology relies on pattern recognition algorithms trained on disease-specific breath 'fingerprints,' supported by a proprietary international encrypted database called the BreathPrint Base, which aggregates anonymous breath data from each screening to improve diagnostic accuracy over time.

The company conducted multicenter validation studies with academic medical centers including Medisch Spectrum Twente, Radboudumc, Maastricht UMC+, Ziekenhuis Bernhoven, Erasmus MC, and the University Hospital Basel in Switzerland. Results of the lung cancer validation study were accepted for publication in the Chest journal. The company pursued integration with hospital Electronic Patient Record systems through a partnership with InterSystems using the IRIS4Health platform, demonstrated at the HIMSS Global Health Conference in 2023. Pricing has not been publicly disclosed, and commercial deployment appears to have been pending rather than active at the time of operational shutdown.

As of 2024, the company has terminated all activities and paused operations, with its website indicating that activities are awaiting funding. No funding rounds, revenue figures, or ownership structure have been publicly disclosed in the available data. The company served Dutch and Swiss academic hospitals as clinical validation partners rather than paying commercial customers during the documented period.

Name

The eNose Company

Legal name

The eNose Company

Website

https://enose.nl

Company type

Private

Founded year

2013

Operating status

Closed

Headcount range

11–50 employees

Short description

The eNose Company develops aeoNose, a portable breath analysis device using VOC pattern recognition for non-invasive detection of lung cancer, colorectal cancer, and COVID-19, serving hospital and academic medical center clients in the Netherlands and Switzerland. Operations are currently paused awaiting funding.

Ownership category

akta.pro rank

Product category

Medical Breath Analysis Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI)

Keywords

• Electronic nose devices
• Breath analysis diagnostics
• Medical breath testing
• VOC detection technology
• Non-invasive disease screening

Headquarters

HQ city

Zutphen

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. aeoNose Device Sales: Sale of the aeoNose hardware device to hospitals and healthcare providers for use in clinical settings. Device provides breath analysis for lung cancer, colorectal cancer, and COVID-19 detection.
2. Data Services: Anonymous encrypted data from screenings is stored in the BreathPrint Base database, contributing to an expanding knowledge base that improves diagnostic accuracy over time.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

The eNose Company develops and manufactures the aeoNose, a portable electronic nose device that detects volatile organic compound (VOC) fingerprints in exhaled breath to non-invasively identify lung cancer, colorectal cancer, and COVID-19. Each test is conducted with a disposable HEPA-filtered mouthpiece, delivers results within 15 minutes, and feeds anonymous data into the proprietary BreathPrint Base database that improves diagnostic accuracy with each screening. The company has completed multicenter clinical validation studies with leading Dutch and Swiss hospitals.

Product overview

The eNose Company offers a single unified product, the aeoNose, a portable breath analysis device designed for non-invasive disease detection. The device analyzes volatile organic compounds (VOCs) in exhaled breath to identify 'fingerprints' associated with lung cancer, colorectal cancer, and COVID-19. Test results are stored in the patient's confidential medical record, while anonymous aggregated data is encrypted and stored in the company's BreathPrint Base database. The system is designed for use in hospitals with results available within 15 minutes.

Differentiator

Problem solved

Functional benefit

Brands

• aeoNose: Portable breath analysis tool for detecting lung cancer, colorectal cancer, and COVID-19 through volatile organic compound (VOC) profiling in exhaled breath.

Products and services

• aeoNose Portable electronic nose device that detects volatile organic compound (VOC) fingerprints in exhaled breath to non-invasively screen for lung cancer, colorectal cancer, and COVID-19. Uses disposable HEPA-filtered mouthpieces, delivers results within 15 minutes, and is intended for use by healthcare professionals in hospitals and clinical settings.
• BreathPrint Base

Quantifiable outcome

• 15-minute breath test duration
• +1 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and major.

• InterSystemscoreTechnology or IntegrationIntegration partnership using IRIS4Health Intersystems platform for communication between aeoNose and Electronic Patient Record (EPD) systems. Enables seamless data flow between breath analysis device and hospital information systems at HIMSS Global Health Conference 2023 demonstration.
• Medisch Spectrum TwentecoreStrategic or Co-development PartnerLeading Dutch hospital where multicenter validation studies for lung cancer detection were conducted. Dr. Sharina Kort, pulmonologist in training, led research together with Prof. Job van der Palen, clinical epidemiologist.
• RadboudumccoreStrategic or Co-development PartnerAcademic medical center in Nijmegen involved in both lung cancer and colorectal cancer validation studies. Prof. Michel van den Heuvel (pulmonologist) and Prof. Peter Siersema (MDL-arts) served as principal investigators.
• University Hospital BaselmajorStrategic or Co-development PartnerSwiss university hospital participating in multicenter validation study for lung cancer detection alongside Dutch top clinical hospitals, demonstrating international reach of validation research.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Owlstone Medical: Owlstone Medical is a UK-based breath biopsy company developing exhaled breath VOC diagnostics for cancer (lung, colorectal) and other diseases. It is the most direct competitor to The eNose Company, using similar VOC-based pattern recognition for non-invasive disease detection targeting the same hospital customer base.
• Breathomix (formerly Sensigent): Breathomix develops electronic nose technology for medical and industrial applications, with a focus on disease detection through breath analysis. Direct peer competing in the same e-nose category for medical diagnostics.
• ndd Medical Technologies: ndd Medical Technologies manufactures portable pulmonary function testing devices (spirometers) used in hospitals and clinics. Comparable as a portable breath-based diagnostic device company with overlapping pulmonary diagnostics customers.

Emerging players

• Respirix: Respirix is developing breath-based diagnostics for heart failure and other conditions using electronic nose technology. Comparable in approach (VOC pattern recognition) but focused on different indications.
• Mensana Health Diagnostics: Mensana is developing breath-based point-of-care diagnostic devices, with overlap in VOC-based disease detection methodology. Comparable emerging player in the same diagnostic space.
• Spirosure / Fenom Pro: Spirosure develops point-of-care pulmonary function testing devices including the Fenom Pro breath analyzer. Comparable as a portable breath-based respiratory diagnostic device targeting similar clinical settings.

Broad incumbents

• Vitalograph: Vitalograph is an established manufacturer of respiratory diagnostic devices including spirometers and COPD screening tools. Comparable as a broader incumbent in respiratory diagnostics serving hospitals and pulmonary function labs.
• Cosmed: Cosmed manufactures pulmonary function testing equipment, metabolic carts, and cardiopulmonary diagnostic devices. Comparable as a broader incumbent in the pulmonary/respiratory diagnostic device space.
• Philips Breathomics: Philips has invested in breathomics research for lung disease detection as part of its broader respiratory and diagnostics portfolio. Comparable as a large incumbent exploring breath-based diagnostics, though not a focused competitor.

Others

• InterSystems (partnership): InterSystems is a healthcare data platform provider and integration partner of The eNose Company via IRIS4Health. Listed as an ecosystem participant enabling EPD integration rather than direct competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/the-enose-company

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The eNose Company